Cannabinoid CB1 receptors have been a potential target for nonopioid-based pain treatment, but actually targeting the pathway has been hindered by issues with tolerance and unwanted CNS side effects.

The drug, known as VIP36, targets the body’s cannabinoid receptor type 1 (CB1). It was found to be effective in three different animal models for pain and does not appear to cause the harmful side ...

Led by researchers at the University of Laval in Canada, the study found that mice with increased levels of cannabinoid receptor 1 (CB1) on certain brain cells show significantly fewer behaviors ...

The drug, known as VIP36, targets the body's cannabinoid receptor type 1 (CB1). It was found to be effective in three different animal models for pain and does not appear to cause the harmful side ...

Two videoconferences will be held tomorrow, March 27, 2025in French at 05:30pm CET and in English at 07:30pm CET (02:30pm ET) ...

Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development ...

They bind to a receptor, called cannabinoid receptor one (CB1), on the surface of brain cells and on pain-sensing nerve cells throughout the body. Working with collaborators at Stanford University ...